Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 416 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo (0.9% Sodium chloride) infusion Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

NCT07038200
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Dystrophy, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), FSH Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Interventions
AOC-1020, Placebo
Drug
Lead sponsor
Avidity Biosciences, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
14
States / cities
Orange, California • Palo Alto, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Intravenous Thyroxine for Heart-Eligible Organ Donors

NCT04415658
View directory record Official record
Conditions
Brain Death, Heart Failure
Interventions
Thyroxine, Saline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
14 Years to 55 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
14
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated Phase 4 Interventional Results available

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

NCT03988842
View directory record Official record
Conditions
Pulmonary Embolism With Acute Cor Pulmonale, Pulmonary Embolism, Pulmonary Embolism With Pulmonary Infarction, Pulmonary Embolism Subacute Massive, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Alteplase, Unfractionated heparin, Placebo, Apixaban
Drug
Lead sponsor
Victor Tapson, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 13, 2026, 9:15 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients

NCT07810946
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Abstinence, Alcohol Use Disorder
Interventions
Sodium Acetate, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

NCT01746784
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
N6022, Normal saline
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
17
States / cities
Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 4 Interventional Results available

Intravenous Acetaminophen for Non-Narcotic Postoperative Pain Management Following Knee Arthroscopy

NCT02025634
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Intravenous Acetaminophen, Placebo (0.9% Normal Saline infusion)
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma

NCT03469934
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Etokimab, Placebo
Biological · Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Normal, Illinois • Novi, Michigan • Edmond, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

Prehospital Tranexamic Acid Use for Traumatic Brain Injury

NCT01990768
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
1 gram Tranexamic Acid (TXA), 2 grams TXA, 0.9% Sodium Chloride injectable
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Minneapolis, Minnesota • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

NCT02609789
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy
Interventions
JNJ-55920839, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

NCT00009620
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Intracranial Hemorrhages
Interventions
Phenobarbital, Saline
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Female only
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 1997
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)

NCT00145327
View directory record Official record
Conditions
Osteoporosis
Interventions
Zoledronic Acid, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
68 Years to 90 Years · Female only
Enrollment
2,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
30
States / cities
Tucson, Arizona • Little Rock, Arkansas • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

NCT05659264
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
mRNA-0184, Placebo
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Not applicable Interventional Results available

Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion

NCT01126593
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
0.5% bupivacaine, Normal Saline
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years to 90 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
Dociparstat sodium, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 13, 2026, 9:15 PM EDT
Recruiting Phase 4 Interventional

Low-Dose Ketamine Infusion During Burn Wound Care

NCT06506565
View directory record Official record
Conditions
Burn, Pain, Dissociation, Opioid
Interventions
Ketamine, 0.9% NaCl
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 13, 2026, 9:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

NCT01983241
View directory record Official record
Conditions
Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions
Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

NCT04722666
View directory record Official record
Conditions
Major Depressive Disorder With Suicidal Ideation With Intent
Interventions
MIJ821 Intravenous Injection, Placebo Intravenous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Farmington, Connecticut • Oakland Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

NCT05717062
View directory record Official record
Conditions
Snakebite, Envenoming, Snake
Interventions
Varespladib intravenous form, varespladib-methyl- oral form, Placebo intravenous form, Placebo - oral form
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 13, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

NCT04384523
View directory record Official record
Conditions
Ascites Hepatic
Interventions
OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV, OsrHSA 140 mg/kg IV, OsrHSA 200 mg/kg IV, Placebo
Drug · Other
Lead sponsor
Healthgen Biotechnology Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 13, 2026, 9:15 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 13, 2026, 9:15 PM EDT
Active, not recruiting Phase 3 Interventional

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

NCT05037123
View directory record Official record
Conditions
Chronic Postsurgical Pain
Interventions
Continuous ketamine infusion, Ketamine + Saline, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 13, 2026, 9:15 PM EDT
Withdrawn Phase 2 Interventional

Mechanisms Underlying Predictors of Success From Obesity Surgery

NCT02697253
View directory record Official record
Conditions
Obesity
Interventions
Exendin 9-39 and Sitagliptin, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 13, 2026, 9:15 PM EDT